84
Participants
Start Date
January 25, 2011
Primary Completion Date
October 16, 2012
Study Completion Date
November 12, 2012
Cadazolid
Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
Vancomycin
Vancomycin, provided as capsules (125 mg) for oral administration
Placebo-matching cadazolid
Placebo of cadazolid powder for oral suspension
Placebo-matching vancomycin
Placebo of vancomycin capsules
Clinical Investigative Site 6735, Modena
Clinical Investigative Site 6902, Newark
Clinical Investigative Site 6734, Busto Arsizio
Clinical Investigative Site 6930, Decatur
Clinical Investigative Site 6935, Marietta
Clinical Investigative Site 6919, Jacksonville
Clinical Investigative Site 6938, Orlando
Clinical Investigative Site 6903, Columbus
Clinical Investigative Site 6936, Royal Oak
Clinical Investigative Site 6632, Cologne
Clinical Investigative Site 6906, Chicago
Clinical Investigative Site 6702, Örebro
Clinical Investigative Site 6914, Houston
Clinical Investigative Site 6915, Idaho Falls
Clinical Investigative Site 6634, Ulm
Clinical Investigative Site 6633, Regensburg
Clinical Investigative Site 6917, Boston
Clinical Investigative Site 6605, Victoria
Clinical Investigative Site 6601, Montreal
Clinical Investigative Site 6606, Sherbrooke
Clinical Ivestigative Site 6602, Calgary
Clinical Investigative Site 6801, Blackpool
Clinical Investigative Site 6804, York
Lead Sponsor
Actelion
INDUSTRY